Fig. 5

Inhibition of GPX2 improves the therapeutic effects of lenvatinib against HCC via promoting ERS in vivo. A Images of subcutaneous tumors in C57BL/6 mice treated with lenvatinib after subcutaneous injection of Hepa1-6 cells transfected with sh-NC or sh-GPX2 lentivirus (n = 6 per group). B A quantification of the tumor weight was performed for each group of subcutaneous tumors. C Time-dependent growth curves of subcutaneous tumor volumes were plotted. D Western blotting to detect the effect of lenvatinib or sh-GPX2 on the expression of GPX2, ATF4, CHOP, and p-PERK in subcutaneous tumors. E–H The gray value results of the Western blotting experiment in subcutaneous tumor groups. Each experiment is conducted in triplicate, and the represented data are SD (±) mean for each experiment. *P < 0.05